Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 15/20 | 0.63 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.63 |
| ▸ | CCR2 | P41597 | 4/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5418807 | 0.91 | ROCK2 (0.70) | ROCK2ROCK1CCR2CHRM4PARP1 | |
| SCHEMBL5410943 | 0.91 | ROCK2 (0.65) | ROCK2ROCK1CCR2CHRM4HRH3 | |
| SCHEMBL5425140 | 0.89 | ROCK2 (0.63) | ROCK2ROCK1CCR2CHRM4PARP1 | |
| SCHEMBL5407087 | 0.86 | ROCK2 (0.71) | ROCK2ROCK1CCR2CHRM4HRH3 | |
| SCHEMBL5419426 | 0.85 | ROCK2 (0.61) | ROCK2ROCK1CCR2CHRM4HRH3 | |
| SCHEMBL5406967 | 0.84 | ROCK2 (0.73) | ROCK2ROCK1CCR2CHRM4PARP1 | |
| SCHEMBL5408985 | 0.84 | ROCK2 (0.65) | ROCK2ROCK1CCR2CHRM4HRH3 | |
| SCHEMBL5419449 | 0.84 | ROCK2 (0.68) | ROCK2ROCK1CCR2CHRM4PARP1 | |
| SCHEMBL5409543 | 0.82 | ROCK2 (0.65) | ROCK2ROCK1CCR2CHRM4HRH3 | |
| SCHEMBL5415837 | 0.81 | ROCK2 (0.67) | ROCK2ROCK1CCR2CHRM4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ROCK2 2/4885ROCK1 1/4885CCR2 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.